Assoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.
Lire la suiteVisite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $4000 - $5000 |
Thyroïdectomie | $5000 - $7500 |
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $4000 - $5000 |
Thyroïdectomie | $5000 - $7500 |
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $4000 - $5000 |
Thyroïdectomie | $5000 - $7500 |
Né en 1981 à Erzincan. Après avoir terminé le lycée Beşiktaş Atatürk Anadolu en 1999, il est entré à l'université d'Istanbul Çapa, à la faculté de médecine.
En 2005, j'ai obtenu mon master et j'ai commencé à pratiquer à l'hôpital d'État de Yüksekova. Il a obtenu son doctorat à l'hôpital de formation et de recherche Okmeydanı dans le service de chirurgie générale. En tant que spécialiste en chirurgie générale, il a travaillé à l'hôpital d'État Zonguldak Atatürk pendant 5 ans et à l'hôpital de formation et de recherche Sancaktepe Şehit Prof. Dr. İlhan Varank pendant 3 ans.
A travaillé en tant que professeur adjoint à l'université Medipol d'Istanbul, au département de chirurgie générale. Travaille actuellement à l'hôpital Pendik de l'université Medipol.
Lire la suiteEducation:
2021 ULUDAĞ ÜNİVERSİTESİ, KULAK BURUN BOĞAZ HASTALIKLARI
2014 EGE ÜNİVERSİTESİ, TIP FAKÜLTESİ
Experience:
2023 - 2023 SAĞLIK BİLİMLERİ ÜNİVERSİTESİ SULTAN ABDÜLHAMİD HAN EĞİTİM VE ARAŞTIRMA HASTANESİ
2021 - 2022 ŞEHİT PROF.DR. İLHAN VARANK SANCAKTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ
Lire la suiteProfesseur de médecine, chef du département d'endocrinologie et de métabolisme, faculté de médecine, université de médecine de Vienne. Membre de plusieurs organisations, telles que la section d'endocrinologie de l'Union européenne des médecins spécialistes et la Société autrichienne d'endocrinologie. Plus de 300 publications dans des revues à comité de lecture couvrant les domaines de la recherche clinique, fondamentale et translationnelle.
Lire la suiteLe Dr. est chef d'équipe en endocrinologie chirurgicale à l'Université médicale de Vienne. Il est spécialiste en chirurgie générale et viscérale et a obtenu un doctorat en médecine (2005). Il a organisé plusieurs conférences et est membre de plusieurs sociétés médicales. Il dirige actuellement le groupe de travail sur l'endocrinologie chirurgicale à l'université médicale de Vienne. Il a reçu le prix Venia Docendi en 2017 et le prix Sandoz pour la recherche sur la thyroïde en 2010.
Lire la suiteProfesseur, spécialiste en endocrinologie pédiatrique
Consultant en endocrinologie pédiatrique
Lire la suiteLe Dr Ilana Itzhakov est endocrinologue au centre médical Ichilov (centre médical Sourasky de Tel-Aviv).
Lire la suiteEducation:
Roles in Projects:
Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.
Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.
Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.
Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).
Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
Lire la suiteEducation and Experience
2014 : La première thyroïdectomie orale robotisée au monde développée par Kim Hoon-yub
2011 ~ : Fellow de l'International Society of Neuro Monitoring Research
2008 ~ : Membre permanent de la Société coréenne des chirurgiens endoscopiques et laparoscopiques
2008 ~ : Membre permanent de la Société coréenne d'oncologie chirurgicale
2008 ~ : Membre permanent de l'Association Thyroïdienne Asie Océanie
2014 ~ : Professeur chercheur, Société coréenne des chirurgiens endoscopiques et laparoscopiques
2014 ~ : Membre du comité de planification de l'Association coréenne des chirurgiens thyroïdiens et endocriniens, membre du comité consultatif des droits médicaux
2012 ~ : Membre du Forum International de Recherche en Chirurgie
2015 ~ : Membre de l'American Thyroid Association
2015 ~ 2016 : Professeur de recherche, Division de chirurgie de la tête et du cou, Faculté de médecine de l'Université Johns Hopkins, États-Unis
Lire la suite
Visite du médecin | prix sur demande |
Thyroïdectomie | $7734 - $9139 |
Medical Interests
Obesity
Insulin resistance
Diabetes
Hypoglycemia (low sugar)
Growth retardation and short stature
Anorexia
growth hormone deficiency
Puberty problems (early puberty, delayed puberty, excessive hair growth, menstrual irregularity, polycystic ovary syndrome)
Turner syndrome
Thyroid diseases (Goiter, hypothyroidism, hyperthyroidism, Hashimoto’s disease, thyroid nodule)
Sexual development disorders (small penis, undescended testis, gender ambiguity, hypospadias)
Adrenal gland diseases (Congenital adrenal hyperplasia, Addison’s disease, Cushing’s syndrome)
Bone and calcium metabolism diseases (rickets, vitamin D deficiency, osteoporosis)
Education
Bachelor’s - Master’s: Ankara University Faculty of Medicine (1998-2004)
Ph.D. - Specialization in Medicine: Child Health and Diseases, Dr. Sami Ulus Gynecology and Childhood Health and Diseases Training and Research Hospital (2005-2010)
Ph.D. - Minor specialization: Pediatric Endocrinology, Dokuz Eylul University Faculty of Medicine (2010-2013)
Experience
Child Health and Diseases Specialist Diyarbakır Children’s Hospital 2010
Pediatric Endocrine Minor Assistant Dokuz Eylül University Medical Faculty Hospital 2010-2014
Pediatric Endocrinology Specialist İzmir Tepecik Training and Research Hospital 2014-2015
Assistant Professor Izmir Katip Celebi University Faculty of Medicine 2015-2016
Associate Professor Izmir Katip Celebi University Faculty of Medicine 2016-2021
Pediatric Endocrinology Associate Professor Ulus Liv Hospital 2021- Present
Pediatric Endocrinology Associate Professor Vadistanbul Liv Hospital 2021- Present
Memberships
Aegean Child Endocrine and Diabetes Association, Member, 2010
Pediatric Endocrinology and Diabetes Association, Member, 2010
Growing Child Association, Member, 2014
European Society of Pediatric Endocrinology (ESPE), Member, 2016
Lire la suiteExperience
İSTİNYE UNIVERSITY FACULTY OF MEDICINE
Liv Hospital
Liv Hospital Ulus
Acıbadem Bodrum Hospital
Tatvan State Hospital
Tatvan State Hospital
CLEVELAND CLINIC
Dokuz Eylul University Faculty of Medicine
Education
DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY
Dokuz Eylül University, General Surgery
AKDENİZ UNIVERSITY, FACULTY OF MEDICINE
Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.
Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.
Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.
Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?
Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.
Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Thyroïdectomie | $4000 - $5500 |
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Lire la suite
Visite du médecin | prix sur demande |
Thérapie à l'iode radioactif | $5000 - $7000 |
Thyroïdectomie | $4000 - $5500 |